Who is sponsoring NCT03866460?

NCT03866460 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT03866460?

Interventions in NCT03866460: Distortion product otoacoustic emission measurement (DPOAE).

What condition does NCT03866460 study?

NCT03866460 studies Intraocular Retinoblastoma, Hearing Loss.

Is NCT03866460 still recruiting?

NCT03866460 is currently completed. Last updated 7 November 2024.

Last reviewed 2024-11-07 · How we verify

NCT03866460

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

Completed Last updated 7 November 2024

What this trial tests

trial testing Distortion product otoacoustic emission measurement (DPOAE) in Intraocular Retinoblastoma in 30 participants. Completed in 4 November 2024.

Timeline

6 March 2019

Primary endpoint
4 November 2024

4 November 2024

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	6 March 2019
Primary completion	4 November 2024
Estimated completion	4 November 2024
Sites	1 location across United States

Drugs / interventions tested

Distortion product otoacoustic emission measurement (DPOAE)

Conditions studied

Intraocular Retinoblastoma — all drugs for Intraocular Retinoblastoma →
Hearing Loss — all drugs for Hearing Loss →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

Adults 3 Months to 18, any sex, with Intraocular Retinoblastoma or Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03866460 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03866460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing